Initiatives

BG Medicine is applying its proprietary systems biology biomarker discovery platform to some of the pharmaceutical industry's greatest challenges and to important global healthcare problems.

	Leading a FDA Critical Path Initiative to discover new biomarkers of liver toxicity.
	Leading a pre-competitive approach to solve the leading cause of heart attacks.
	Conducting a biomarker discovery project for TB drug development, in collaboration with the TB Alliance.